Hubei Cancer Hospital
Clinical trials sponsored by Hubei Cancer Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Blood tests may predict flap complications in breast reconstruction Results expected Sep 2026 (estimated)
- Double-Target immunotherapy added to standard care for aggressive cervical cancer Results expected Dec 2026 (estimated)
- Gut bacteria could be key to stopping cancer Drug's diarrhea side effect Results expected Jun 2027 (estimated)
- Nipple fluid DNA test could spare thousands from unnecessary breast surgery Results expected Jun 2027 (estimated)
-
Can a Triple-Drug combo before surgery eliminate EGFR-Mutant lung cancer?
Cure Not yet recruitingThis phase II trial tests whether giving a combination of firmonertinib, anlotinib, and chemotherapy before surgery can shrink or eliminate tumors in people with resectable EGFR-mutant non-small cell lung cancer. The study enrolls adults with stage IIA-IIIB disease who have speci…
Phase 2 • Sponsor: Hubei Cancer Hospital • Aim: Cure
Last updated Sep 10, 2026 00:00 UTC
-
Pain pills vs. cancer treatment: new study investigates opioid impact on immunotherapy
Knowledge-focused Not yet recruitingThis study looks at how opioid painkillers affect the success of immunotherapy in 100 people with advanced lung cancer who have moderate to severe pain. Researchers want to see if better pain control helps immunotherapy work better, and whether opioids themselves change the treat…
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC